NAVIGATING LIFE BEYOND TREATMENT INTEGRATING CLINICAL CARE AND QUALITY OF LIFE IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS

Background: Prognosis and survival rates are dismal for triple-negative breast cancer (TNBC), one of the most aggressive kinds. The main therapies for TNBC include chemotherapy, surgery, and radiation, however, they may have long-term effects on clinical findings and QOL that need additional investigation. Objective: Current research evaluates medicines' clinical outcomes and TNBC patients' physical, emotional, and well-being. Methods: Tracking 100 TNBC patients two years after therapy. Clinic criteria were survival, recurrence, CPR, down staging, lymph node involvement, and metastasis. This study assessed the quality of life at baseline, 6 months, and 1 year after therapy using the SF 36 for physical and mental health, FSS, BDI-II, GAD-7, MOS-SSS, and WHOQOL-BREF. We assessed statistical significance using p-values (p≤0.05) and 95% confidence intervals. Results: The clinical data showed 72.56±8.15% overall survival, 30.37±5.12% recurrence, and 18.19±3.44% metastasis. The reduction in tumor size was 2.83±0.53 cm, with 40.28% of patients obtaining CPR. Patients with pathological axillary lymph node metastases had 25.66 ± 4.15%. Patients who survived exhibited substantially higher physical and mental well-being scores (72.44±10.14 and 75.17±9.66) than those who had recurrence or metastasis. Patients without pathological remaining tumors had the highest mean QOL score (82.19±12.29) while those with metastases had the lowest (50.12±6.58). Conclusion: Patients with TNBC receive therapy and quality-of-life measures. Critical issues and clinical outcomes, such as survival and recurrence rate, show that comprehensive treatment improves disease management and survivors' QOL. These findings underline the necessity for integrated TNBC therapy to improve prognosis and quality of life.